KORU Medical Systems, Inc. (KRMD)
| Market Cap | 160.49M -8.3% |
| Revenue (ttm) | 46.27M +18.4% |
| Net Income | -823,382 |
| EPS | -0.02 |
| Shares Out | 43.38M |
| PE Ratio | n/a |
| Forward PE | 59.44 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 219,102 |
| Open | 3.660 |
| Previous Close | 3.690 |
| Day's Range | 3.510 - 3.800 |
| 52-Week Range | 2.860 - 6.608 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 6.13 (+65.54%) |
| Earnings Date | Nov 10, 2026 |
About KRMD
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver,... [Read more]
Financial Performance
In 2025, KORU Medical Systems's revenue was $41.13 million, an increase of 22.23% compared to the previous year's $33.65 million. Losses were -$2.64 million, -56.52% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for KRMD stock is "Buy." The 12-month stock price target is $6.13, which is an increase of 65.54% from the latest price.
News
KORU Medical Systems Registration statement: Registration filing
KORU Medical Systems filed a registration statement on November 16, 2026, providing details about a securities offering with the SEC.
Koru Medical files $100M mixed securities shelf
06:17 EST Koru Medical (KRMD) files $100M mixed securities shelf
Koru Medical price target lowered to $4.50 from $5 at Piper Sandler
Piper Sandler analyst Jason Bednar lowered the firm’s price target on Koru Medical (KRMD) to $4.50 from $5 and keeps a Neutral rating on the shares. The firm notes the…
KORU Medical Systems Transcript: Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
Q3 growth was 11%, with a second consecutive EBITDA-positive quarter and FY revenue guidance raised to $48 million–$48.5 million. International expansion, RYSTIGGO uptake and Freedom360 development support the growth outlook, with profitability expected next year.
KORU Medical Systems Earnings Call Transcript: Q3 2026
Q3 revenue rose 11% YoY to $11.6M, with 65.2% gross margin and a second consecutive profitable quarter. Guidance increased across revenue, gross margin and year-end cash, with high-teens Q4 growth expected.
KORU Medical Systems Earnings release: Q3 2026
KORU Medical Systems released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
KORU Medical Systems Slides: Q3 2026
KORU Medical Systems has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 10, 2026.
KORU Medical Systems Quarterly report: Q3 2026
KORU Medical Systems has published its Q3 2026 quarterly earnings report on November 10, 2026.
KORU Medical Systems Announces Third Quarter 2026 Results Including Second Consecutive Quarter of Positive Net Income and Adjusted EBITDA
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems to Participate in Upcoming Investor Conferences
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializ...
KORU Medical Systems to Report Third Quarter 2026 Financial Results on November 10, 2026
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializ...
KORU Medical Systems Slides: Conference presentation
KORU Medical Systems has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
KORU Medical Systems Slides: Corporate presentation
KORU Medical Systems has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Koru Medical price target lowered to $6 from $7 at Craig-Hallum
Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on Koru Medical (KRMD) to $6 from $7 and keeps a Buy rating on the shares following Q2 earnings, which exceeded…
KORU Medical Systems Earnings Call Transcript: Q2 2026
Q2 revenue grew 18% year-over-year to $12M, with strong domestic and international expansion and a return to positive net income. Guidance was narrowed due to international launch timing, but gross margin outlook was raised and long-term growth catalysts remain robust.
KORU Medical Systems Earnings release: Q2 2026
KORU Medical Systems released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
KORU Medical Systems Quarterly report: Q2 2026
KORU Medical Systems has published its Q2 2026 quarterly earnings report on August 5, 2026.
KORU Medical Systems Slides: Q2 2026
KORU Medical Systems has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializ...
Kaskela Law LLC Announces Investigation of KORU Medical Systems, Inc. (KRMD) and Encourages Long-Term KRMD Shareholders to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating KORU Medical Systems, Inc. (Nasdaq: KRMD) (“KORU”) on behalf of the company's current shareholders.The investigation seeks to determine whet...
KORU Medical Systems to Report Second Quarter 2026 Financial Results on August 5, 2026
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializ...
KORU Medical Systems Slides: Investor presentation
KORU Medical Systems has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on innovative and patient-centric large volume ...
Koru Medical reports Q1 revenue $11.77M, consensus $11.28M
16:14 EDT Koru Medical (KRMD) reports Q1 revenue $11.77M, consensus $11.28M